Clinical and analytical evaluation of the Alinity m HR HPV assay within the VALGENT-3 framework

Last updated on 26-3-2021 by Sharon Dhillon

Public Access


Peer reviewed scientific article





Only clinically validated human papillomavirus (HPV) tests should be used in cervical cancer screening. VALGENT provides a framework to validate new HPV tests. In the VALGENT-3 study, the clinical accuracy of the recently launched Abbott Alinity m HR HPV assay (Alinity m) to detect cervical precancerous lesions was assessed against the standard comparator test (Hybrid Capture 2; HC2) and additionally against two previously validated alternative comparator tests (Abbott RealTime HR HPV and Roche cobas 4800 assays). Validation was conducted using 1,300 consecutive cervical samples from women …

Associated health topics:

QR code

QR code for this page URL